Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

2.

Infant outcomes after maternal antiretroviral exposure in resource-limited settings.

Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, Shapiro DE, Mofenson L, Moran L, Campbell TB, Hitti J, Fiscus S, Currier J; ACTG 5190/PACTG 1054 Study Team.

Pediatrics. 2012 Jun;129(6):e1525-32. doi: 10.1542/peds.2011-2340. Epub 2012 May 14.

3.

Treatment 2.0: catalysing the next phase of scale-up.

Hirnschall G, Schwartländer B.

Lancet. 2011 Jul 16;378(9787):209-11. doi: 10.1016/S0140-6736(11)60247-X. Epub 2011 Feb 25. No abstract available.

PMID:
21353697
4.

Better mind the gap: addressing the shortage of HIV-positive women in clinical trials.

d'Arminio Monforte A, González L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL; Women for Positive Action.

AIDS. 2010 May 15;24(8):1091-4. doi: 10.1097/QAD.0b013e3283390db3. No abstract available.

PMID:
20386426
5.

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team.

Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Erratum in: Clin Infect Dis. 2008 Dec 15;47(12):1611.

PMID:
18781872
6.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7.

PMID:
17971713
7.

Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.

Sánchez-Conde M, Palacios R, Sanz J, Rodríguez-Novoa S, Rivas P, Santos J, Sola J, Asensi V, de Mendoza C, Estrada V, Barreiro P, González-Lahoz J, Jiménez-Nacher I, Soriano V.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1237-41.

PMID:
17961110
8.

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

Molina JM, Journot V, Furco A, Palmer P, De Castro N, Raffi F, Morlat P, May T, Rancinan C, Chêne G; Montana (ANRS 091) Study Group.

Antivir Ther. 2007;12(3):417-22.

PMID:
17591032
9.
10.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
11.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group.

N Engl J Med. 2006 Jan 19;354(3):251-60.

12.
13.

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team.

J Infect Dis. 2005 Mar 15;191(6):830-9. Epub 2005 Feb 10.

PMID:
15717256
14.

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team.

JAMA. 2004 Jul 14;292(2):180-9.

PMID:
15249567
15.

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M.

J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9.

PMID:
15247553
17.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team.

N Engl J Med. 2004 Apr 29;350(18):1850-61.

18.

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM.

J Infect Dis. 2004 Apr 1;189(7):1176-84. Epub 2004 Mar 16.

PMID:
15031785
19.

Combining dependent tests for linkage or association across multiple phenotypic traits.

Xu X, Tian L, Wei LJ.

Biostatistics. 2003 Apr;4(2):223-9.

PMID:
12925518
20.

Supplemental Content

Support Center